title: PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?
authors: Labmed Directorate, St. James's Hospital, Dublin, Ireland. Electronic address: sgray@stjames.ie.
authors: Steven G
authors: SG
authors: Gray
authors: HOPE Directorate, St. James's Hospital, Dublin, Ireland.
authors: Sinéad
authors: S
authors: Cuffe
authors: Department of Histopathology and Morbid Anatomy, Trinity College Dublin, Dublin, Ireland.
authors: Stephen P
authors: SP
authors: Finn
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000235:genetics*; D015415:Biomarkers / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D059447:Cell Cycle Checkpoints / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D017403:In Situ Hybridization / Q000379:methods*; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D015415:Biomarkers; C423236:CD274 protein, human; D012333:RNA, Messenger